Iradimed Corporation Announces Second Quarter 2018 Financial Results
• Reports second quarter 2018 revenue of $7.4 million
• Reports second quarter 2018 GAAP diluted EPS of $0.11 and non-GAAP diluted EPS of $0.14
• Increases full year 2018 revenue, GAAP and non-GAAP diluted earnings guidance
Winter Springs, Florida, July 31, 2018 – IRADIMED CORPORATION (NASDAQ:IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system that is designed to be safe for use during MRI procedures, today announced financial results for the three and six months ended June 30, 2018.
For the second quarter ended June 30, 2018, the Company reported revenue of $7.4 million compared to $5.5 million for the second quarter 2017. Net income was $1.4 million, or $0.11 per diluted share, compared to a net income of $0.4 million, or $0.03 per diluted share for the second quarter 2017. Gross profit margin was 76.8 percent, compared to 77.7 percent for the second quarter 2017. Domestic sales were 77.7 percent of total revenue, compared to 87.7 percent for the second quarter 2017. Revenue from sales of our patient vital signs monitor was $1.5 million for the second quarter 2018 compared to $0.3 million for the second quarter 2017.
Non-GAAP net income was $1.7 million for the quarter ended June 30, 2018, which excludes $0.3 million of stock compensation expense, net of tax. Non-GAAP net income for the quarter ended June 30, 2017 was $0.7 million, which excludes $0.3 million of stock compensation expense, net of tax. Non-GAAP earnings per diluted share was $0.14, compared to $0.06 for the second quarter 2017. Free cash flow was $1.5 million, compared to $0.1 million for the second quarter 2017.
For the six months ended June 30, 2018, the Company reported revenue of $14.5 million compared to $10.7 million for the same period in 2017. Net income was $2.2 million, or $0.18 per diluted share, compared to a net income of $0.1 million, or $0.01 per diluted share for the same period in 2017. Gross profit margin was 76.5 percent, compared to 75.5 percent for the same period in 2017. Domestic sales were 80.5 percent of total revenue, compared to 85.7 percent for the same period in 2017. Revenue from sales of our patient vital signs monitor was $2.7 million for the six months ended June 30, 2018, compared to $0.7 million for the same period in 2017.
Non-GAAP net income was $2.8 million for the six months ended June 30, 2018, which excludes $0.6 million of stock compensation expense, net of tax. Non-GAAP net income for the same period in 2017 was $0.7 million, which excludes $0.5 million of stock compensation expense, net of tax. Non-GAAP earnings per diluted share for the six months ended June 30, 2018 was $0.24, compared to $0.06 for the same period in 2017. Free cash flow was $3.0 million for the six months ended June 30, 2018, compared to $(0.3) million for the same period in 2017.
As of June 30, 2018, the Company had combined cash and investments of $29.5 million.
“I am very satisfied with these results as they continue to show strength in the demand for our products and the earnings potential that exists within our business,” said Roger Susi, President and Chief Executive Officer of the Company.
For the third quarter 2018, the Company expects to report revenue of $7.4 million to $7.5 million, GAAP diluted earnings per share of $0.07 to $0.08 and non-GAAP diluted earnings per share of $0.09 to $0.10.
The Company increased its revenue guidance for the full year 2018 and now expects to report revenue of $29.5 million to $30.1 million. The Company previously expected full year 2018 revenue of $29.3 million to $30.0 million.
The Company also increased its earnings guidance for the full year 2018 and now expects to report GAAP diluted earnings per share of $0.35 to $0.37 and non-GAAP diluted earnings per share of $0.45 to $0.47. The Company previously expected full year 2018 GAAP diluted earnings per share of $0.30 to $0.33 and non-GAAP diluted earnings per share of $0.40 to $0.43.
The Company’s non-GAAP earnings per share guidance excludes stock-based compensation expense, net of tax, which the Company expects to be approximately $1.3 million and $0.3 million for the full year and third quarter 2018, respectively.
Use of non-GAAP Financial Measures
The Company believes the use of non-GAAP net income, free cash flow and infrequent income tax items are helpful to our investors. These measures, which we refer to as our non-GAAP financial measures, are not prepared in accordance with GAAP. We calculate non-GAAP net income as net income excluding stock-based compensation expense, net of tax. Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a company’s non-cash expenses, we believe that providing non-GAAP financial measures that exclude stock-based compensation expense allows for meaningful comparisons between our operating results from period to period. We calculate free cash flow as net cash provided by operating activities less net cash used in investing activities for purchases of property and equipment. We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investing in our business, making strategic acquisitions, strengthening our balance sheet and returning cash to our shareholders via share repurchases. Infrequent tax items are considered based on their nature and are excluded from the provision for income taxes as these costs or benefits are not indicative of our normal or future provision for income taxes. All of our non-GAAP financial measures are important tools for financial and operational decision making and for evaluating our operating results.
A reconciliation of the non-GAAP financial measures used in this release to the most comparable U.S. GAAP measures for the respective periods can be found in the table later in this release immediately following the condensed statements of cash flows. These non-GAAP financial measures should not be considered in isolation or as a substitute for a measure of the Company’s operating performance or liquidity prepared in accordance with U.S. GAAP and are not indicative of net income or cash provided by operating activities.
IRADIMED has scheduled a conference call to discuss this announcement beginning at 11:00 a.m. Eastern Time today, July 31, 2018. Individuals interested in listening to the conference call may do so by dialing 1-844-413-1781 for domestic callers, or 1-716-247-5767 for international callers, and entering the reservation code 2194419.
The conference call will also be available real-time via the internet at http://www.iradimed.com/en-us/investors/events/. A recording of the call will be available on the Company’s website following the completion of the call.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in the development of innovative magnetic resonance imaging (“MRI”) compatible medical devices. We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system that is specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely-designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically-ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The IRADIMED 3880 has a compact, lightweight design allowing it to travel with the patient from their critical care unit, to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the IRADIMED 3880 include: wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; non-invasive blood pressure; patient temperature, and; optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The IRADIMED 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.
For more information please visit www.iradimed.com.
This press release contains forward-looking statements as defined in the Private Securities Litigation Act of 1995, particularly statements regarding our expectations, beliefs, plans, intentions, future operations, financial condition and prospects, and business strategies. These statements relate to future events or our future financial performance or condition and involve unknown risks, uncertainties and other factors that could cause our actual results, level of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. The risks and uncertainties referred to above include, but are not limited to, risks associated with the Company’s ability to receive FDA 510(k) clearance for new products; unexpected costs, delays or diversion of management’s attention associated with the design, manufacture or sale of new products; the Company’s ability to implement successful sales techniques for existing and future products and evaluate the effectiveness of its sales techniques; additional actions by or requests from the FDA; our significant reliance on a single product; unexpected costs, expenses and diversion of management attention resulting from the FDA warning letter; potential disruptions in our limited supply chain for our products; a reduction in international distribution; actions of the FDA or other regulatory bodies that could delay, limit or suspend product development, manufacturing or sales; the effect of recalls, patient adverse events or deaths on our business; difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services; changes in laws and regulations or in the interpretation or application of laws or regulations.
Further information on these and other factors that could affect the Company’s financial results is included in filings we make with the Securities and Exchange Commission from time to time. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update forward-looking statements.
Chief Financial Officer IRADIMED CORPORATION